#United States #patient-centered #Florida Cancer Specialists #Fort Myers #Oncology Care

Transforming Cancer Care: Insights from the Patient-Centered Oncology Care Conference

The landscape of oncology care is rapidly evolving, and Florida Cancer Specialists & Research Institute (FCS) stands at the forefront of this transformation. With over 40 years of experience in community-based cancer care, FCS is dedicated to improving patient outcomes and accessibility to groundbreaking therapies. Recent contributions by FCS leaders at the Patient-Centered Oncology Care® (PCOC) conference served to highlight both the challenges and opportunities within the field, providing necessary insights for the ongoing evolution of modern oncology practices.

A Focus on Patient-Centered Care

During the 2026 PCOC conference, FCS president and managing physician, Dr. Lucio N. Gordan, presented key findings from the 2026 JJ Oncology Care Index. This annual report provides a comprehensive view of the oncology landscape from provider perspectives, particularly focusing on community settings where the majority of patients receive treatment. Dr. Gordan emphasized the need for ongoing adaptation to new treatments and clinical guidelines. "Our patients trust us to deliver the best care possible," he asserted, underscoring FCS's commitment to sharing these insights to enhance care quality and accessibility.

Navigating the Rapid Changes in Oncology

The pace at which cancer care is advancing is staggering. Dr. David Wenk, FCS Assistant Managing Physician, acknowledged this rapid change, stating that it underscores the importance of collaborative efforts to improve care. This collaboration is vital as FCS works alongside other oncology leaders to examine the trends and innovations shaping cancer treatment approaches. The discussions at the conference revolved around how clinical guidelines and formulary strategies impact patient access, along with showcasing innovative care delivery methods.

Key Contributions from FCS Leaders

FCS's commitment to shaping oncology care is also reflected through the contributions of several leaders at the conference:

• - Josh Eaves, FCS Chief Development and Strategy Officer: He presented on techniques to scale oncology practices to meet future patient needs, emphasizing the necessity for growth and adaptation in a dynamic healthcare environment.
• - Kiana Mehring, Senior Vice President: Offered insights from a payer's perspective on guidelines concordance and how they affect healthcare delivery, enriching the discussion on cooperation between different stakeholders in the healthcare system.
• - Kristen Boykin, Senior Director of Pharmacy Operations: Her presentation focused on the crucial role oncology pharmacy plays in integrating new therapies early into patient care, illustrating how medication management can enhance treatment efficacy.
• - Jeanine Ksar, Clinical Oncology Pharmacist: Provided an overview on therapy selection, discussing the transition from FDA approval to practical application in cancer centers, and the importance of navigating this process effectively.

Innovation and Access

With a robust clinical research program, FCS consistently leads the way in innovative cancer therapies. The collaboration with Sarah Cannon Research Institute (SCRI) positions FCS as a significant player in clinical trials—especially as many FDA-approved cancer drugs were accessible to patients via clinical trials at FCS before their general release. This proactive approach not only enhances cancer treatment options for patients at FCS but also bolsters the entire oncology field.

By conducting more than 180 active clinical trials each year, FCS is not only improving patient care but also accelerating oncology research and development. Their dedicated team of highly trained physicians is focused on creating tailored treatment plans that leverage advanced precision oncology innovations to improve patient outcomes.

Conclusion

Overall, the contributions and insights from FCS at the 2026 Patient-Centered Oncology Care conference reflect an unwavering commitment to advancing cancer care. As the healthcare landscape continues to evolve, FCS's role in shaping policy and fostering innovation will remain crucial for the future of oncology. With a strong emphasis on patient-centered approaches and collaborative practices, FCS exemplifies what it means to remain at the leading edge of cancer treatment and research, dedicated to enhancing the lives of cancer patients today and in the future.